Ezetimibe and bile acid sequestrants

Couture, Patrick; Lamarche, Benoı̂t

doi:10.1097/mol.0b013e3283613a55

Cited by 27 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the percent reduction in LDL-C in our study and studies involving HIV-infected patients is not as high as in studies involving non-HIV infected patients. In non-HIV studies with ezetimibe added on therapy LDL-C was decreased by 25-60 % [ 10 ]. This suggests that HIV-infected patients are less affected by this therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been used as a second-line therapy for patients who are unable to tolerate high dose statins or in those who do not achieve therapeutic lipid target levels [ 10 ]. In HIV-dyslipidemia, ezetimibe is safe and can be used in patients with poor response to statins and those receiving protease inhibitors [ 10 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…The aim of the current study was to assess whether HIV-infected patients treated with a combination of rosuvastatin 10 mg plus ezetimibe 10 mg show a greater improvement in their lipid profile compared to an increased dose of rosuvastatin (from 10 to 20 mg). Several studies in non-HIV populations have shown that co-administration of rosuvastatin plus ezetimibe is safe, and achieved significant improvements in lipid profiles in high-risk patients compared to monotherapy [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

et al. 2015

View full text Add to dashboard Cite

BackgroundHIV-infected patients on antiretroviral therapy frequently develop dyslipidemias and, despite therapy with potent lipid-lowering agents, a high percentage does not achieve guideline recommended lipid targets. In this study, we examined the efficacy of combination treatment with a statin and the cholesterol transport blocker, ezetimibe, vs. monotherapy with a statin in HIV-infected patients not achieving lipid goals.MethodsThis was a 12-week, prospective, randomized, open-label clinical trial. Patients were eligible if they had an apolipoprotein B (apoB) >0.80 g/L despite therapy with rosuvastatin 10 mg daily for a minimum of 12 weeks. Patients were randomized to take ezetimibe 10 mg/rosuvastatin 10 mg or rosuvastatin 20 mg for 12 weeks. Percentage and absolute change in apoB (primary outcome), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apoliporpotein A1 (apoA1), apoB/apoA1, TC/HDL-C, atherogenic index of plasma (API), and high-sensitivity C-reactive protein (hsCRP) were compared. Changes in safety parameters (such as AST, ALT, CK) and clinical symptoms were also assessed.ResultsForty-three patients (23 on ezetimibe 10 mg/rosuvastatin 10 mg and 20 on rosuvastatin 20 mg) completed the trial. Baseline characteristics did not differ between the groups. Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Significant between-group differences were observed for mean TC (-1.01 mmol/L vs. -0.50 mmol/L, p = 0.03), TG (-0.62 mmol/L vs -0.17 mmol/L, p = 0.03), and non-HDL-C (-0.97 mmol/L vs. -0.53 mmol/L, p = 0.03) all in favour of the ezetimibe plus rosuvastatin group. Two patients, both in the rosuvastatin 20 mg group, experienced mild myalgias; neither discontinued the study.ConclusionsThe addition of ezetimibe to rosuvastatin appears to be safe in patients with HIV. Furthermore, the combination of ezetimibe and rosuvastatin improved TG, AIP and non-HDL cholesterol levels more than a dose increase in rosuvastatin in patients with HIV-associated dyslipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Селективно тормозит всасывание ХС в тонкой кишке за счёт угнетения активности транспортера ХС NPC1L1 [17,18].…”

Section: ингибиторы всасывания хс: эзетимибunclassified

Pharmacological targets for dislipidemies correction. Opportunities and prospects of therapeutic usage

et al. 2018

View full text Add to dashboard Cite

Literature data on influence of existing and new groups of drug preparations for dyslipidemias correction are systemized, and molecular mechanisms of their effects are reviewed. The results of experimental and clinical investigations aimed at revealing of new pharmacological targets of dyslipidemias correction were analyzed. The approaches for activation of high density lipoproteins functionality are described. The implementation of alternative preparations with new alternative mechanisms of action may be suggested to improve the effectiveness of traditional treatment in the future.

show abstract

“…For example, a statin might be combined with a cholesterol absorption inhibitor or a bile acid sequestrant which both work in the intestine to prevent cholesterol absorption [ 44 , 45 ]. The FDA also approved PCSK9 inhibitor antibodies, neutralising circulating PCSK9, a protein associated with LDLR degradation in the liver for the treatment of FH patients [ 46 ]. These monoclonal antibodies are not expected to work in HoFH with LDLR null-mutations, given the mode of action of PCSK9 on the LDLR protein which requires a functional LDLR.…”

Section: Management Of Fhmentioning

confidence: 99%

The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry

Al-Allaf¹,

H.Nazar²,

Alnefaie³

et al. 2017

TOCMJ

View full text Add to dashboard Cite

Background:Familial hypercholesterolemia (FH) is a life-threatening inherited condition. Untreated patients have the risk to develop raised plasma levels of cholesterol, atherosclerosis and cardiovascular disease (CVD). If diagnosed and treated early in life, the pathological consequences due to atherosclerosis could be avoided and patients with FH can have an anticipated normal life. Mounting evidence suggests that FH is underdiagnosed and undertreated in all populations. The underlying molecular basis of FH is the presence of mutations in one or more genes in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin 9 (PCSK9). However, their prevalence is largely unknown in Saudi Arabia but given the high rates of consanguinity, the prevalence appears to be higher. Furthermore, the high prevalence of obesity and diabetes mellitus in Saudi Arabia increases the vascular disease burden in FH cases by adding additional CVD risk factors.Objective:This article explores the spectrum of FH-causing mutations in the highly consanguineous Saudi community, the need for establishing the Saudi FH registry, the challenges in creating gene databases, and cascade screening.Conclusion:The establishment of FH registry and genetic testing should raise awareness not only among healthcare professionals, but the general population as well. It also helps to provide the best treatment regimen in a cost effective manner to this under-recognised population of FH patients.

show abstract

Ezetimibe and bile acid sequestrants

Cited by 27 publications

References 53 publications

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Pharmacological targets for dislipidemies correction. Opportunities and prospects of therapeutic usage

The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry

Contact Info

Product

Resources

About